NEW YORK (GenomeWeb News) – Agilent Technologies reported after the close of the market on Thursday a 2 percent bump in revenues during its fiscal first quarter but missed analyst estimates on the top and bottom lines.

Total revenues for the three months ended Jan. 31 came in at $1.68 billion, up from $1.64 billion during the first quarter of Fiscal Year 2012, but just short of the average analyst estimate of $1.69 billion.

Orders in the quarter reached $1.71 billion, a 6 percent increase from $1.62 billion a year ago.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.